Apppendix to "The Association Between Primary Care Physician Compensation and Patterns of Care Delivery, 2012-2015"

Adrian Garcia Mosqueira, M.A.; Meredith Rosenthal, Ph.D. and Michael L. Barnett, M.D., M.S.

Table of Contents

Appendix Methodology: Methodology Behind Low-Value and High-Value Composite Measures

Table A1: Low-Value and High-Value Care Measure Definitions

Table A2: Patient and Physician Characteristics by Ownership

Table A3: Factors Affecting Compensation (FACs) for Physician Owners

Table A4: Out-of-Visit/Office Care by PCP Ownership

Table A5: Overuse and Quality Measures by Ownership

Table A6: Out-of-Visit/Office Care by PCP Compensation Type, Alternate Compensation Definition

Table A7: Overuse and Quality Measures – Full Adjusted and Unadjusted Models, Alternate Compensation Definition

Appendix Methodology: Methodology Behind Low-Value and High-Value Composite Measures

We developed two composite measures from the 20 quality measures defined in Appendix Table 2. The two composite measures integrated two mutually exclusive groups of quality measures, 8 measures for low-value care and 12 measures for high-value care (Appendix Table 2). A critical component in creating these measures is that a single office visit may be eligible for multiple quality measures. For instance, if a patient with coronary artery disease (CAD) and congestive heart failure (CHF) presents for a visit and is taking aspirin and a beta-blocker but no statin or angiotensin-converting enzyme (ACE) inhibitor, that visit would be eligible for 5 high value measures and receive "credit" for 3 of those measures (1 for aspirin and 2 for beta-blocker), or a composite high-value score of 3/5 = 0.6. Therefore, for the composite measures, each visit has a number of eligible measures (denominator) and the number of times the service measured was delivered (numerator).

We also needed to account for the fact that a visit which is eligible for multiple services should have more weight than a visit with only one service. To accomplish this, for the calculation of survey-weighted estimates of the composite measures, we multiplied the survey weights provided by NAMCS by the number of eligible services for a given visit. Therefore, a visit with 5 eligible services would have 5 times its typical weight than a visit with 1 service. We used these modified survey weights for regressions that included the composite measures.

Table A1 – Low-Value and High-Value Care Measure Definitions

Table A1 -		High-Value Care Mea		
Low-Value	Quality Measure	Denominator Population	Numerator	Exclusions
Care Measure	Antibiotics for "never" URI's	New problem visits with primary diagnosis or reason for visit including: bronchitis, nonstreptococcal phary ngitis or upper respiratory infections	Prescription of any oral antibiotic	"Competing diagnosis" for antibiotics including urinary tract infection, other bacterial infections, vaginitis, human immunodeficiency virus. Also excluded patients with chronic obstructive pulmonary disease or any cancer diagnosis, as well as patients sent to the emergency department or admitted.
	Screening EKG in GME	Any visit with a diagnosis or reason for visit of annual physical exam	Order for EKG	Any diagnosis or reason for visit of chronic sinusitis, immune disorders, nasal polyps, eye/orbit related injuries, or head trauma.
	Screening CBC in GME	Any visit with a diagnosis or reason for visit of annual phy sical exam	Order for CBC	Any diagnosis or reason for visit of cancer, hematologic disease, fever, fatigue or bacterial infection
	Screening UA in GME	Any visit with a diagnosis or reason for visit of annual phy sical exam	Order for a UA	Any diagnosis or reason for visit of urologic disease or symptom [dy suria, urgency, retention, hematuria], kidney disease in chronic kidney disease, or pregnancy.
	Opioids for back/neck pain	Any visit with a diagnosis or reason for visit involving back or neck pain	Prescription of any opioid- containing medication	Any diagnosis or reason for visit including "red flags": fever, weight loss, cachexia, neurologic symptoms, cancer, spinal fracture, my elopathy, post-laminectomy Any diagnosis or reason for visit
	CT/MRI for back/neck pain	Any visit with a diagnosis or reason for visit involving back or neck pain	Order of advanced imaging (CT/MRI)	including "red flags": fever, weight loss, cachexia, neurologic symptoms, cancer, spinal fracture, myelopathy, post-laminectomy
	Opioids for headache	Any visit with a diagnosis or reason for visit of headache or migraine	Prescription of any opioid- containing medication	Any diagnosis or reason for visit of human immunodeficiency virus, pregnancy, neurologic symptoms [weakness, sensory changes, altered mental status], cancer, head trauma or epilepsy
	CT/MRI for headache	Any visit with a diagnosis or reason for visit of headache or migraine	Order of advanced imaging (CT/MRI)	Any diagnosis or reason for visit of human immunodeficiency virus, pregnancy, neurologic symptoms [weakness, sensory changes, altered mental status], cancer, head trauma or epilepsy
	Tobacco cessation counseling	Any visit for a current cigarette smoker or diagnosis/reason for visit for smoking	Tobacco cessation counseling provided	None
High Value Care Measures	Weight reduction counseling	Any visit for a patient with a body mass index greater than or equal to 30, or a diagnosis/reason for visit of obesity	Counseling provided for weight reduction, exercise, or diet/nutrition	None
	Anticoagulant use in Afib	Any visit with a diagnosis of atrial fibrillation or atrial flutter	Prescription of hep arin-family drug, coumadin, novel anticoagulant, aspirin or Aggrenox	Any diagnosis or reason for visit of gastrointestinal bleeding, gastritis, alcoholism or drug abuse, gait disorder, dementia, central nervous system bleeding, seizures, central nervous system malignancy, or thrombocytopenia
	Aspirin use in CAD	Any visit with a diagnosis or reason for visit or chronic illness code for coronary artery disease	Prescription of an antiplatelet agent including aspirin	Any diagnosis or reason for visit of gastrointestinal bleeding, gastritis, central nervous system bleeding
	Beta blocker use in CAD	Any visit with a diagnosis or reason for visit or chronic illness code for coronary artery disease	Prescription of a beta blocker	Any diagnosis of heart block, asthma or chronic obstructive pulmonary disease
	Statin use in CAD	Any visit with a diagnosis or reason for visit or chronic illness code for coronary artery disease	Prescription of a statin	Any diagnosis of liver disease or alcoholism
	Beta blocker use in CHF	Any diagnosis or chronic illness code of congestive heart failure Any diagnosis or chronic	Prescription of a beta blocker	Any diagnosis of heart block, asthma or chronic obstructive pulmonary disease
	ACE/ARB use in CHF	illness code of congestive heart failure	Prescription of an ACE or ARB	Any diagnosis of hyperkalemia or angioedema

Antiplatelet use in CVD	Any diagnosis or chronic illness code of congestive heart failure	Prescription of an antiplatelet agent including aspirin	Any diagnosis or reason for visit of gastrointestinal bleeding, gastritis, central nervous system bleeding
Statin use in DM	Any diagnosis or chronic illness code of diabetes mellitus	Prescription of a statin	Any diagnosis of liver disease or alcoholism
Depression counseling	Any diagnosis of depression or chronic illness code of depression	Prescription of antidepressant (SSRI, SNRI, TCA etc) or mental health counseling	None
Treatment for osteoporosis	Any diagnosis of osteoporosis or chronic illness code for osteoporosis	Prescription for osteoporosis medication (bisphosphonate, PTH, etc)	None

 $Table \ A2-Patient \ and \ Physician \ Characteristics \ by \ Ownership$

	Own Solo		Own Non-Solo		
(n raw)	27,154		22,081		
(n weighted)	574,548,344		597,514,201		
Age (mean)	39	[36.4 – 41.7]	42.9	[40.8 - 45.0]	
Female	61.40%	[0.59 - 0.64]	60.50%	[0.58 - 0.63]	
Race/Ethnicity					
Non-Hispanic White	70.70%	[0.68 - 0.74]	58.10%	[0.55 - 0.62]	
Non-Hispanic Black	11.10%	[0.09 - 0.13]	13.00%	[0.11 - 0.15]	
Hispanic	13.10%	[0.11 - 0.15]	21.70%	[0.18 - 0.25]	
Non-Hispanic Other	5.00%	[0.04 - 0.06]	7.20%	[0.05 - 0.09]	
Number of Chronic Diseases					
0	50.10%	[0.46 - 0.54]	44.60%	[0.41 - 0.48]	
1	19.00%	[0.18 - 0.20]	21.30%	[0.20 - 0.23]	
2	12.30%	[0.11 - 0.13]	15.00%	[0.13 - 0.17]	
3	9.20%	[0.08 - 0.11]	10.10%	[0.09 - 0.11]	
4+	9.40%	[0.07 - 0.12]	9.00%	[0.08 - 0.10]	
Region					
Northeast	24.10%	[0.20 - 0.28]	20.50%	[0.16 - 0.25]	
Midwest	18.00%	[0.15 - 0.21]	11.80%	[0.09 - 0.15]	
South	32.60%	[0.29 - 0.37]	43.70%	[0.39 - 0.49]	
West	25.30%	[0.20 - 0.31]	24.00%	[0.19 - 0.29]	
Rural Visit Location	8.30%	[0.07 - 0.10]	11.20%	[0.08 - 0.14]	
Insurance Type					
Private	63.30%	[0.60 - 0.67]	47.20%	[0.44 - 0.51]	
M edicare	20.30%	[0.16 - 0.24]	22.80%	[0.21 - 0.25]	
Medicaid/CHIP	13.50%	[0.12 - 0.16]	23.10%	[0.19 - 0.27]	
Other	2.90%	[0.02 - 0.03]	6.90%	[0.06 - 0.08]	
Practice Characteristics					
Who Owns the Practice?					
Physician Grp.	97.60%	[0.96 - 0.99]	98.70%	[0.97 - 1.00]	
Acad/Commty	0.00%	[0.00 - 0.00]	0.00%	[0.00 - 0.01]	
Insurer/HMO	2.30%	[0.01 - 0.04]	0.00%	[0.00 - 0.02]	
Capitation Revenue					
0-25% Revenue	60.20%	[0.55 - 0.66]	66.80%	[0.61 - 0.73]	
26-50% Revenue	5.20%	[0.03 - 0.07]	9.70%	[0.05 - 0.15]	
51-75% Revenue	5.50%	[0.00 - 0.11]	2.80%	[0.02 - 0.04]	
Over 75% Revenue	1.40%	[0.00 - 0.02]	2.60%	[0.01 - 0.04]	
Missing	28.00%	[0.23 - 0.32]	18.00%	[0.14 - 0.22]	

Note: Table presents estimates of sample demographic characteristics stratified by ownership type 95% CI in brackets.

Table A3 – Factors Affecting Compensation (FACs) for Physician Owners

Own Solo	Own Non-Solo
1,035	1,133
205,769	181,459
72.88%	71.30%
[0.69-0.77]	[0.68-0.75]
33.70%	57.80%
[0.30-0.38]	[0.54-0.62]
4.40%	9.80%
[0.03-0.06]	[0.07-0.13]
6.90%	14.80%
[0.05-0.09]	[0.12-0.18]
5.85%	8.52%
[0.04-0.08]	[0.06-0.11]
	1,035 205,769 72.88% [0.69-0.77] 33.70% [0.30-0.38] 4.40% [0.03-0.06] 6.90% [0.05-0.09]

Note: Chi squared p-value for differences in FACs across ownership status is 0.00 at the 95% C.I. Physicians could check more than one FAC in the survey, thus these totals are not mutually exclusive.

Table A4 - Out-of-Visit/Office Care by PCP Ownership

	Percentage [95% C.I.]	Unadjusted O.R. [95% C.I.]	Adjusted O.R. [95% C.I.]
Home Visits	-		-
Own Solo	4.6% [0.30 – 0.60]	1.29 [0.51 – 3.26]	0.88 [0.21 - 3.67]
Own Non-Solo	11.5% [0.09 – 0.14]	3.49 [1.41 – 8.59] ***	2.04 [0.50 - 8.35]
Nursing H Visits			
Own Solo	15.7% [0.12 – 0.19]	0.90 [0.49 – 1.66]	1.23 [0.48 – 3.17]
Own Non-Solo	19.5% [0.16 – 0.23]	1.18 [0.67 – 2.08]	1.19 [0.48 – 2.97]
Hospital Visits			
Own Solo	53.7% [0.49 – 0.58]	2.63 [1.66 – 4.17] ***	2.28 [1.09 – 4.73] **
Own Non-Solo	46.0% [0.42 – 0.50]	1.93 [1.22 – 3.07] ***	1.76 [0.84 – 3.69]
Phone Consults			
Own Solo	53.3% [0.49 – 0.58]	1.86 [1.16 – 2.98] **	3.07 [1.46 – 6.43] ***
Own Non-Solo	62.7% [0.59 – 0.67]	2.74 [1.70 – 4.40] ***	4.64 [2.18 – 9.84] ***
Email Consults			
Own Solo	16.5% [0.13 – 0.19]	1.15 [0.69 – 2.15]	1.42 [0.60 – 3.33]
Own Non-Solo	12.6% [0.09 – 0.16]	0.83 [0.43 – 1.59]	1.43 [0.59 – 3.51]
Observations (raw/weighed)	7,819/623,039		

Note: **p<0.05 ***p<0.01
*Adjusted model uses productivity-based employee physicians as reference category. Adjusters are patient demographics, such as racial/ethnic, urban/rural, age, gender and number of chronic conditions, as well as practice-level characteristics including percentage of revenue from Medicare, Medicaid and private insurance, revenue subject to capitation, and electronic health records availability.

Table A5 - Overuse and Quality Measures by Ownership

	Owner Solo			Owner Non-Solo		
Quality/Overuse Measure	N	%	95% CI	N	%	95% CI
Overuse Composite	4798	35.83%	[0.33-0.39]	4391	36.50%	[0.33-0.40]
Antibiotics for "never" URIs	390	56.89%	[0.46-0.68]	414	59.64%	[0.52-0.68]
Screening EKG in GME	2085	6.91%	[0.04-0.10]	1487	6.77%	[0.04-0.09]
Screening CBC in GME	2745	24.93%	[0.21-0.29]	2082	24.05%	[0.20-0.28]
Screening UA in GME	2810	21.75%	[0.18-0.26]	2111	16.67%	[0.13-0.20]
Opioids for back/neck pain	1093	32.21%	[0.27-0.37]	1467	40.50%	[0.34-0.47]
CT/MRI for back/neck pain	1093	5.02%	[0.03-0.07]	1467	4.45%	[0.03-0.06]
Opioids for headache	340	12.93%	[0.08-0.18]	309	14.25%	[0.08-0.21]
CT/MRI for headache	340	1.84%	[0.01-0.03]	309	0.37%	[0.00-0.01]
High Value Composite	9588	34.81%	[0.32-0.37]	8920	34.05%	[0.32-0.36]
Tobacco cessation counseling	2438	9.84%	[0.08-0.12]	2284	11.67%	[0.09-0.14]
Weight reduction counseling	4946	20.23%	[0.17-0.23]	4649	18.87%	[0.16-0.22]
Anticoagulant use in Afib	223	64.92%	[0.55-0.75]	185	64.87%	[0.54-0.76]
Aspirin use in CAD	588	33.78%	[0.25-0.42]	518	37.60%	[0.29-0.46]
Beta blocker use in CAD	479	44.66%	[0.35-0.55]	424	54.63%	[0.46-0.63]
Statin use in CAD	588	38.69%	[0.30-0.48]	524	46.61%	[0.38-0.55]
Beta blocker use in CHF	262	44.14%	[0.35-0.54]	245	42.37%	[0.29-0.56]
ACE/ARB use in CHF	372	17.54%	[0.11-0.24]	329	18.45%	[0.13-0.24]
Antiplatelet use in CVD	396	32.02%	[0.23-0.41]	307	31.00%	[0.24-0.38]
Statin use in DM	2235	36.91%	[0.32-0.41]	2226	37.13%	[0.33-0.41]
Depression counseling	2121	49.38%	[0.45-0.54]	1784	47.61%	[0.43-0.52]
Treatment for osteoporosis	711	19.08%	[0.15-0.23]	601	24.05%	[0.17-0.31]

Note: Abbreviations: confidence interval (CI), upper respiratory tract infection (URI), computed tomography (CT), electrocardiogram (ECG), complete blood count (CBC), urinalysis (UA), general medical examination (GME), magnetic resonance imaging (MRI), atrial fibrillation (AF), coronary artery disease (CAD), congestive heart failure (CHF), angiotensin-converting enzy me inhibitor (ACE), angiotensin receptor blocker (ARB), cerebrovascular disease (CVD), diabetes mellitus (DM).

^{*}All estimates are survey-weighted proportions accounting for NAMCS sample design.

^{**} Low- and high-value care composites calculated at the visit level as the proportion of low- or high-value services delivered at a visit. To account for visits qualifying for more services than others, survey weights were multiplied by the number of eligible low- or high-value measures.

Table A6 - Out-of-Visit/Office Care by PCP Compensation Type, Alternate Compensation Definition

This definition of compensation defines the exposure as those physicians that select only personal productivity or practice finances FACs.

	Percentage [95% C.I.]	Unadjusted O.R. [95% C.I.]	Adjusted O.R. [95% C.I.]
Home Visits		<u>.</u>	
Reference PCPs	3.9% [0.03 - 0.06]	-	-
Productivity FACs	7.6% [0.06 - 0.09]	2.07 † [1.26 – 3.45]	1.98* [1.13 – 3.48]
Nursing H Visits			
Reference PCPs	13.1% [0.10 - 0.17]	-	-
Productivity FACs	15.4% [0.13 - 0.18]	1.21 [0.87 – 1.69]	0.83 [0.49 – 1.42]
Hospital Visits			
Reference PCPs	36.1% [0.32 - 0.40]	-	-
Productivity FACs	46.6% [0.44 - 0.49]	1.54 † [1.26 – 1.89]	1.04 [0.75 – 1.45]
Phone Consults			
Reference PCPs	56.2% [0.52 - 0.60]	-	-
Productivity FACs	54.4% [0.52 - 0.57]	0.93 [0.76 – 1.14]	0.79 [0.58 – 1.08]
Email Consults			
Reference PCPs	24.0% [0.21 - 0.28]	-	-
Productivity FACs	14.8% [0.13 - 0.17]	0.55 † [0.42 – 0.71]	0.69 * [0.49 – 0.97]
Observations (raw/weighed)	7,620/633,815		

Note: *p<0.05 †p<0.01

^{*}Adjusted model uses productivity-based employee physicians as reference category. E.H.R uses partial as reference. Adjusters are patient demographics, such as racial/ethnic, urban/rural, age, gender and number of chronic conditions, as well as practice-level characteristics including percentage of revenue from Medicare, Medicaid and private insurance, electronic health records availability, ownership status, and solo/group practice.

Table A7 - Overuse and Quality Measures – Full Adjusted and Unadjusted Models, Alternate Compensation Definition

This definition of compensation defines the exposure as those physicians that select only personal productivity or practice finances FACs.

	Overuse Composite		High Value Composite	
(n raw)	75,516		3,026	
(n weighted)	1,026,046,733		16,192,336	
	Undj. O.R. [95% CI]	Adj. O.R. [95 % CI]	Undj. O.R. [95% CI]	Adj. O.R. [95 % CI]
Productivity FACs (ref – PCPs with any non-productivity FAC)	1.05	1.04	0.84†	0.93
	[0.89-1.24]	[0.84-1.29]	[0.75-0.95]	[0.80-1.07]

Note: *p<0.05 †p<0.01 Results are odds ratios and 95% confidence intervals in brackets. Compensation reference group is PCPs that have selected clinical factors as FACs.